Format

Send to

Choose Destination
See comment in PubMed Commons below
Med Hypotheses. 2012 May;78(5):675-81. doi: 10.1016/j.mehy.2012.02.009. Epub 2012 Mar 4.

Glutamate-based depression GBD.

Author information

1
Clinical Neuroscience AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA. dennis.mccarthy@astrazeneca.com

Abstract

We describe a new term: glutamate-based depression (GBD). GBD is defined as a chronic depressive illness associated with environmental stress and diseases associated with altered glutamate neurotransmission. We hypothesize that glutamate-induced over-activation of extrasynaptic NMDA receptors in the subgenual cingulate area called Brodmann's 25 plays an important role in the etiology of depression and may be responsible for the high incidence of co-morbid depression associated in diseases with glutamate etiology. While depression is a syndrome with multiple possible etiologies, we propose that a disruption in glutamatergic neurotransmission may underline a substantial proportion of clinically observed depression. The high rates of depressive symptoms associated with various disorders in which altered glutamatergic functions have been identified, may suggest a common pathophysiological mechanism is underlying the diverse clinical presentations.

PMID:
22391030
DOI:
10.1016/j.mehy.2012.02.009
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center